 |
|
|
| |
Time to Viral Suppression Does not Impact SVR in Patients Treated With Glecaprevir/Pibrentasvir
|
| |
| |
Reported by Jules Levin
Infectious Diseases Society of America, October 3-7, 2018, San Francisco, California
Christoph Sarrazin1, Jordan J Feld2, Douglas E Dylla3, Sanjeev Arora4, David Victor III5, Yiran B Hu3, Stanley Wang3, Federico J Mensa3, David Wyles6
1JW Goethe University Hospital, Frankfurt, Germany and St. Josefs-Hospital, Wiesbaden, Germany; 2Toronto Centre for Liver Disease, University of Toronto, Toronto, Ontario, Canada; 3AbbVie Inc., North Chicago, Illinois, United States; 4University of New Mexico, Albuquerque, New Mexico, United States; 5Houston Methodist Hospital, Houston, Texas, United States;
6Denver Health Medical Center, Denver, Colorado, United States
|
| |
|
|
|
|
|
